179 related articles for article (PubMed ID: 20819011)
1. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study.
Leone M; Vila C; McGown C
Expert Rev Neurother; 2010 Sep; 10(9):1399-408. PubMed ID: 20819011
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
3. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study.
Lanteri-Minet M; Díaz-Insa S; Leone M; Vila C; Clissold SP;
Int J Clin Pract; 2010 Jun; 64(7):936-43. PubMed ID: 20584227
[TBL] [Abstract][Full Text] [Related]
5. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
6. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
7. Almotriptan for the treatment of acute migraine: a review of early intervention trials.
Antonaci F; De Cillis I; Cuzzoni MG; Allena M
Expert Rev Neurother; 2010 Mar; 10(3):351-64. PubMed ID: 20187858
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
9. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
10. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
11. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.
Cady RK; Freitag FG; Mathew NT; Elkind AH; Mao L; Fisher AC; Biondi DM; Finlayson G; Greenberg SJ; Hulihan JF
Headache; 2009 Mar; 49(3):350-63. PubMed ID: 19220503
[TBL] [Abstract][Full Text] [Related]
12. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.
Goadsby PJ; Zanchin G; Geraud G; de Klippel N; Diaz-Insa S; Gobel H; Cunha L; Ivanoff N; Falques M; Fortea J
Cephalalgia; 2008 Apr; 28(4):383-91. PubMed ID: 18294251
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of almotriptan in controlled clinical trials.
Mathew NT
Eur Neurol; 2005; 53 Suppl 1():29-33. PubMed ID: 15920335
[TBL] [Abstract][Full Text] [Related]
14. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
15. Improved patient satisfaction and pain evolution with almotriptan in migraine: a primary care study.
Díaz-Insa S; Vila C; McGown CC
Curr Med Res Opin; 2011 Mar; 27(3):559-67. PubMed ID: 21222569
[TBL] [Abstract][Full Text] [Related]
16. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
Diener HC
Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
[TBL] [Abstract][Full Text] [Related]
17. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
Allais G; Acuto G; Cabarrocas X; Esbri R; Benedetto C; Bussone G
Neurol Sci; 2006 May; 27 Suppl 2():S193-7. PubMed ID: 16688629
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
Pascual J
Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study.
Slof J
Appl Health Econ Health Policy; 2012 May; 10(3):201-15. PubMed ID: 22320449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
